For Tina, finally getting a diagnosis of Sjögren’s was a relief. Tina Aswani Omprakash’s hospital bedside table was crowded with an unusual collection of items she regularly used to combat dryness ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in ...

Novartis Entresto® US patent upheld by US Court of Appeals ...

Novartis today announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for PTC518, an HTT mRNA splice modulator with the potential to become the first ...

Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.

Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network ...

Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class complement inhibitor for ...